Novo Ventures
79
35M
59
3.16
22
0.25
36
- Areas of investment
Summary
The main department of described VC is located in the Bagsvu00e6rd. The company was established in Europe in Denmark. Novo Ventures appeared to be a CVC structure as part of the corporation.
Among the most popular portfolio startups of the fund, we may highlight Spectranetics, Alios BioPharma, Cianna Medical. The fund has exact preference in some founders of portfolio startups. If startup sums 4 or 5+ of the founder, the chance for it to be financed is low. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Pharmaceutical, Genetics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Novo Ventures, startups are often financed by Novartis Venture Fund, Novo Holdings, TPG Biotech. The meaningful sponsors for the fund in investment in the same round are TPG Biotech, New Enterprise Associates, Versant Ventures. In the next rounds fund is usually obtained by Novo Holdings, SV Health Investors, TPG Biotech.
Besides them, we counted 7 critical employees of this fund in our database.
The important activity for fund was in 2015. Despite it in 2019 the fund had an activity. Comparing to the other companies, this Novo Ventures performs on 16 percentage points more the average number of lead investments. Considering the real fund results, this VC is 16 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year. The increased amount of exits for fund were in 2014. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Investments analytics
Analytics
- Total investments
- 79
- Lead investments
- 22
- Exits
- 36
- Rounds per year
- 3.16
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (71)
- Health Care (40)
- Therapeutics (30)
- Medical (27)
- Pharmaceutical (25) Show 17 more
- Investments by region
-
- United States (49)
- France (5)
- United Kingdom (12)
- Switzerland (5)
- Netherlands (1) Show 3 more
- Peak activity year
- 2015
- Number of Unicorns
- 3
- Number of Decacorns
- 3
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 13
- Avg. valuation at time of investment
- 154M
- Group Appearance index
- 0.92
- Avg. company exit year
- 9
- Avg. multiplicator
- 2.54
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Amolyt Pharma | 06 Jan 2023 | Health Care, Medical, Therapeutics | Late Stage Venture | 153M | Rhone-Alpes, Écully, France |
| Imagen Biotech | 19 Oct 2011 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 40M | United States, New York, New York |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.